Dudley JC, Lin M-T, Le DT, Eshleman JR. Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res. 2016;22(4):813–20.

CAS  PubMed  Google Scholar 

Lee V, Murphy A, Le DT, Diaz LA Jr. Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist. 2016;21(10):1200–11.

CAS  PubMed  PubMed Central  Google Scholar 

Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. JAMA Oncol. 2015;1(9):1319–23.

PubMed  Google Scholar 

Sauer N, Szlasa W, Jonderko L, et al. LAG-3 as a potent target for novel anticancer therapies of a wide range of tumors. Int J Mol Sci. 2022;23(17):9958. https://doi.org/10.3390/ijms23179958.

Tian X, Ning Q, Yu J, Tang S. T-cell immunoglobulin and ITIM domain in cancer immunotherapy: a focus on tumor-infiltrating regulatory T cells. Mol Immunol. 2022;147:62–70.

CAS  PubMed  Google Scholar 

Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409–13.

CAS  PubMed  PubMed Central  Google Scholar 

Le DT, Kim TW, Cutsem EV, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11–9.

CAS  PubMed  Google Scholar 

Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20.

CAS  PubMed  PubMed Central  Google Scholar 

Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182–91.

CAS  PubMed  PubMed Central  Google Scholar 

Konstantinopoulos PA, Luo W, Liu JF, et al. Phase II study of avelumab in patients with mismatch repair deficient and mismatch repair proficient recurrent/persistent endometrial cancer. J Clin Oncol. 2019;37(30):2786–94.

CAS  PubMed  PubMed Central  Google Scholar 

Azad NS, Gray RJ, Overman MJ, et al. Nivolumab is effective in mismatch repair-deficient noncolorectal cancers: results from arm Z1D—a subprotocol of the NCI-MATCH (EAY131) study. J Clin Oncol. 2020;38(3):214–22.

CAS  PubMed  Google Scholar 

Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777.

PubMed  PubMed Central  Google Scholar 

Diaz LA Jr, Shiu K-K, Kim T-W, et al. Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 2022;23(5):659–70.

CAS  PubMed  PubMed Central  Google Scholar 

Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1):1–10.

CAS  PubMed  Google Scholar 

O’Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study. J Clin Oncol. 2022;40(7):752–61.

CAS  PubMed  PubMed Central  Google Scholar 

Maio M, Ascierto PA, Manzyuk L, et al. Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study. Ann Oncol. 2022;33(9):929–38.

CAS  PubMed  Google Scholar 

Liu X, Fan J, Liaw K-L, et al. Abstract 616: Literature review and meta-analyses of the prevalence of microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) for colorectal (CRC), gastric (GC), endometrial (EC) and ovarian cancers (OC) in Chinese population. Cancer Res. 2019;79(13_Supplement):616.

Google Scholar 

Cui M, Li P, Mao Y, et al. Implication of microsatellite instability in Chinese cohort of human cancers. Cancer Manag Res. 2020;12:10287–95.

CAS  PubMed  PubMed Central  Google Scholar 

Xu J, Mao Y, Xu N, et al. Pembrolizumab in patients from China with microsatellite instability-high/mismatch repair deficient tumors: KEYNOTE-158. Immunotherapy. 2024;16(8):529–37.

Google Scholar 

Li J, Deng Y, Zhang W, et al. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors. J Hematol Oncol. 2021;14(1):95.

CAS  PubMed  PubMed Central  Google Scholar 

Huang J, Song Y, Luo S, et al. Efficacy of HX008 in high microsatellite instability/mismatch repair–defificient (MSI-H/dMMR) solid tumors: results from a multicenter phase II open-label study. J Clin Oncol. 2021;39(15_suppl):2572.

Google Scholar 

Qin S, Li J, Zhong H, et al. Serplulimab, a novel anti-PD-1 antibody, in patients with microsatellite instability-high solid tumours: an open-label, single-arm, multicentre, phase II trial. Br J Cancer. 2022;127(12):2241–8.

CAS  PubMed  PubMed Central  Google Scholar 

Li J, Xu Y, Zang A, et al. Updated analysis from a phase 2 study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable/metastatic microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) solid tumors. J Clin Oncol. 2022;40(4_suppl):1.

Google Scholar